Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Molecular and Cellular Biology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Research Article

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

Dong-Mei Wu, Xin Wen, Xin-Rui Han, Shan Wang, Yong-Jian Wang, Min Shen, Shao-Hua Fan, Zi-Feng Zhang, Qun Shan, Meng-Qiu Li, Bin Hu, Gui-Quan Chen, Jun Lu, Yuan-Lin Zheng
Dong-Mei Wu
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Wen
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin-Rui Han
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shan Wang
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Jian Wang
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Shen
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shao-Hua Fan
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zi-Feng Zhang
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qun Shan
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meng-Qiu Li
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Hu
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gui-Quan Chen
cState Key Laboratory of Pharmaceutical Biotechnology, MOE Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing University, Nanjing, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Lu
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan-Lin Zheng
aKey Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, People's Republic of China
bCollege of Health Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, People's Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/MCB.00259-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In the current study, we were interested in exploring the molecular mechanism of circular RNA DLEU2 (circRNA-DLEU2) (hsa_circ_0000488) and microRNA 496 (miR-496), as well as PRKACB, in human acute myeloid leukemia (AML) cell activities. The RNA expression levels of circRNA-DLEU2, hsa-miR-496, and PRKACB were assessed by quantitative real-time PCR (qRT-PCR). The proliferation and apoptosis abilities of the cells were determined by CCK8 assay and flow cytometry analysis. Target relationships between circRNA-DLEU2 and miR-496, as well as PRKACB, were analyzed by luciferase reporter assay and probe assay. Immunoblotting assays were used to detect the protein expression level of PRKACB. We also did in vivo experiments to observe tumor formation after overexpression of circRNA-DLEU2. Our data showed that circRNA-DLEU2 was upregulated in AML tissues and cells, which promoted AML cell proliferation and inhibited cell apoptosis. circRNA-DLEU2 promoted AML tumor formation in vivo. miR-496 was inhibited by circRNA-DLEU2 and was downregulated in AML tissues. circRNA-DLEU2 inhibited miR-496 expression and promoted PRKACB expression. miR-496 antagonized the effects of PRKACB on MOLM-13 cell proliferation and apoptosis. Collectively, circRNA-DLEU2 accelerated human AML by suppressing miR-496 and promoting PRKACB expression.

INTRODUCTION

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and shows significantly multifaceted biological and clinical heterogeneity within different patients (1). AML is a heterogeneous hematological malignancy with poor prognosis, due in part to rapid disease progression and frequent emergence of drug resistance (2). The current therapeutic approach to leukemia is generally chemotherapy to achieve complete remission. However, severe side effects and complications, such as serious infection and bleeding owing to anticancer drugs, are major problems (3). Several AML prognostic biomarkers have been identified as molecular genetic advances; among them, molecular abnormalities were considered the most crucial factors (4–6). However, more prognostic or predicative biomarkers are required to contribute to AML therapy.

Circular RNAs (circRNAs), a class of endogenous noncoding RNAs (ncRNAs), have a closed-loop structure because of a covalent junction between their 3′ and 5′ ends (7). With the development of high-throughput sequencing technology, a large number of circRNAs have been reported to play indispensable roles in human fetal development, myocardial infarction, and cancer, including hematopoietic malignancies (7–9). Additionally, circRNAs can sponge microRNA (miRNA) to regulate gene expression (10). For instance, hsa_circ_0018289 is upregulated in cervical cancer, which promotes cell proliferation and metastasis by targeting miRNA 497 (miR-497) (11). Memczak et al. demonstrated that circRNA UBAP2 was notably increased in osteosarcoma tissues, which enhanced cell growth and impeded apoptosis both in vitro and in vivo by inhibiting miR-143 expression (12). Recently, evidence regarding the function of circRNAs in AML patients has emerged. Hirsch et al. delineated the expression pattern of nucleophosmin 1 (NPM1) circular RNA in different AML subgroups (13), L'Abbate et al. observed significant overexpression of circPVT1 in amplicons involving chromosome band 8q24 in 23 cases of AML (AML-amp) cases (14), and Li et al. reported that hsa_circ_0004277 can be a novel biomarker for AML treatment (4). To further investigate the roles of circRNAs in the development of AML, we first performed in silico analysis of the AML-specific circRNA microarray and ascertained the differentially expressed circRNA-DLEU2 in cytogenetically normal AML (CN-AML) patients compared with healthy controls. Our study also investigated the effects of circRNA-DLEU2 on the proliferation and reproduction of AML-related cells and its functions in regard to miR-496 and PRKACB.

miRNAs are a subset of small noncoding RNAs that control gene expression in a site-specific manner (15). Accumulating evidence has identified the distinct expression patterns and biological functions of miRNAs in biological processes, including cell differentiation, apoptosis, and metabolism (16). Overexpression of miR-217 inhibited cellular proliferation and enhanced cell chemosensitivity to doxorubicin by the cell apoptosis pathway in AML cells (17). Some studies have clarified the potential roles of miRNAs as diagnostic and prognostic biomarkers in leukemia (18). For example, Li et al. showed that increased expression of miR-181a or miR-181b was significantly associated with longer overall survival (OS) in AML patients (19). Wang et al. found that miR-216b was upregulated in AML and independently conferred a poor prognosis (20). Based on in silico analysis, we selected miR-496 to conduct our study. A previous study verified that miR-496 was downregulated in prostate cancer (21). However, the function of miR-496 in leukemia remains largely unknown.

The PRKACB gene encodes cAMP-dependent protein kinase A (PKA) catalytic subunit β and is located on chromosome 1p31.1 (22). The PRKACB protein belongs to the Ser/Thr protein kinase family and is a pivotal modulator of the cAMP/PKA pathway, which is intimately correlated with a host of cellular processes, including cell reproduction, gene transcription, and metabolism (23). Some studies have reported the interaction of PRKACB and miRNAs in human cancers. For instance, PRKACB could be directly regulated by miR-200c in breast cancer cells (24). Wang et al. demonstrated that inhibition of miR-372 led to reduced translational repression of PRKACB in liver cancer (25). However, few studies have reported the effects of PRKACB on AML development. We explored the relationship of PRKACB and miR-496 in AML.

The current study investigated the molecular mechanism of circRNA-DLEU2 in AML cell activities. We also confirmed that circRNA-DLEU2 acts as an miR-496 sponge, which is negatively correlated with the expression of PRKACB. The present findings have therapeutic implications and may provide novel therapeutic targets for AML.

RESULTS

circRNA-DLEU2 is upregulated in AML.Based on the circRNA microarray GSE94591, we screened for 30 remarkably differentially expressed circRNAs by fold change value and P value between AML patients and a healthy control via bioinformatics analyses. The data were visualized in a clustered heat map with 10 circRNAs upregulated in the healthy control, 15 in better-risk patients, and 15 in poor-risk patients, among which circRNA-DLEU2 (hsa_circ_0000488; chromosome 13, 50680743 to 50681192) was highly expressed in AML samples compared with healthy samples, showing no significant difference between better- and poor-risk AML patients (Fig. 1A). During the validation of our bioinformatics analyses, we observed that circRNA-DLEU2 levels in AML bone marrow (BM) were significantly higher than those in healthy controls (Fig. 1B) (P < 0.001). Additionally, circRNA-DLEU2 in AML cell lines (MOLM-13, HL-60, and MV-4-11) was remarkably upregulated compared with normal cell lines (Fig. 1C) (P < 0.001). Therefore, we decided to focus on the function of circRNA-DLEU2 and selected MOLM-13 and MV-4-11 cell lines to conduct the subsequent experiments.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

circRNA-DLEU2 is upregulated in AML. (A) Heat map showing the differential expression of circRNAs in a healthy control group, a better-risk group, and a poor-risk group. (B) circRNA-DLEU2 expression in AML tissues was higher than that in healthy tissues as detected by qRT-PCR. ***, P < 0.001 compared with the healthy control group. (C) Expression levels of circRNA-DLEU2 in AML cell lines (MOLM-13, HL-60, and MV-4-11) were higher than that in healthy human cells (BMSC). **, P < 0.01; ***, P < 0.001 compared with BMSC. The data are shown as means and SD.

circRNA-DLEU2 promoted the proliferation of AML cells and inhibited cell apoptosis.In order to determine whether circRNA-DLEU2 has a function in AML, we first transfected MOLM-13 and MV-4-11 cells with a circRNA-DLEU2 vector and a si-circRNA-DLEU2 vector (Fig. 2A and B). According to the quantitative real-time (qRT)-PCR results, circRNA-DLEU2 and si-circRNA-DLEU2 recombinant plasmids were successfully expressed in MOLM-13 and MV-4-11 cells (Fig. 2C and D) (P < 0.001). CCK8 assay (Biotechwell, Shanghai, China) results showed that overexpressed circ-DLEU2 promoted cell proliferation, which was impeded by silencing circRNA-DLEU2 using si-circRNA-DLEU2 (Fig. 2E and F) (P < 0.01). Flow cytometry analysis revealed that the overexpression of circ-DLEU2 impaired the apoptosis rate of AML cell lines, which was completely reversed by the knockdown of circ-DLEU2 (Fig. 2G to H) (P < 0.001). All these results showed that the altered circRNA-DLEU2 influences the proliferation and apoptosis rates of MOLM-13 and MV-4-11 cells.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

circRNA-DLEU2 promotes the proliferation of AML cells and inhibits cell apoptosis. (A and B) Construction of circRNA-DLEU2, si-circRNA-DLEU2, and si-ctrl vectors. (C and D) Results of qRT-PCR indicating that cells were successfully transfected with circRNA-DLEU or si-circRNA-DLEU. **, P < 0.001; ***, P < 0.001 compared with a control group. (E and F) Proliferation rates of MOLM-13 cells and MV-4-11 cells in the circ-DLEU2-OE group were higher than in the circ-vector group, and the proliferation rate in the si-DLEU2 group was lower than in the si-ctrl group. *, P < 0.05 compared with the circ-vector group; **, P < 0.01 compared with the si-ctrl group. (G and H) The apoptosis ratio (annexin V-positive cell numbers/total cell numbers) of circ-DLEU2-OE-transfected MOLM-13 cells and MV-4-11 cells was lower than that of the circ-vector-transfected group, and the apoptosis ratio in the si-DLEU2 group was higher than that in si-ctrl group. ***, P < 0.001 compared with the circ-vector group; **, P < 0.01 compared with si-ctrl group. The data are shown as means and SD.

circRNA-DLEU2 promoted AML tumor formation in vivo.In order to further investigate the role of circRNA-DLEU2 in AML-related tumors, we designed and conducted in vivo experiments. Two weeks after injection, we found the tumor volume in mice injected with circRNA-DLEU2-transfected MOLM-13 and MV-4-11 cells was larger than that in mice injected with circ-vector (control [ctrl])-transfected cells (Fig. 3A and B) (P < 0.01). At the same time, we confirmed that the circRNA-DLEU2 expression of mice injected with circRNA-DLEU2-transfected cells was higher than that of mice transfected with circ-vector-transfected cells (Fig. 3C and D) (P < 0.01). Taken together, these data demonstrated that circRNA-DLEU2 accelerates AML-related tumor formation in vivo.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

circRNA-DLEU2 promotes AML tumor formation in vivo. (A and B) Tumor volumes of mice injected with MOLM-13 (A) and MV-4-11 (B) cells transfected with circ-DLEU2. *, P < 0.05; **, P < 0.01 compared with the circ-vector group. (C and D) circRNA-DLEU2 expression in mice injected with MOLM-13 (C) and MV-4-11 (D) cells transfected with circ-DLEU2. **, P < 0.01 compared with the circ-vector group. Five mice were used in each group. The data are shown as means and SD.

miR-496 is inhibited by circRNA-DLEU2 and is downregulated in AML tissues.Considering our results, circRNA-DLEU2 is very likely to be a functional circRNA in AML. As previously reported, one of the common regulatory functions of circRNA is to act as an miRNA sponge and to competitively inhibit its activity. For this purpose, we assumed that circRNA-DLEU2 could serve as an miRNA sponge and might regulate a specific AML-related circRNA-miRNA-mRNA network. To explore the potential miRNA candidates of circRNA-DLEU2, we used the Circular RNA Interactome website (https://circinteractome.nia.nih.gov/bin/mirnasearch) to predict the possible miRNA candidates that can bind circRNA-DLEU2. Four miRNAs (hsa-miR-496, hsa-miR-892a, hsa-miR-487a, and hsa-miR-485-3p) were screened for (the screening criteria were as follows: context+ score percentile, >95, and context+ score, less than −0.2) and are listed in Table 1. Then, we used the OncomiR database (http://www.oncomir.org/oncomir/index.html) to analyze the expression levels of the 4 miRNAs in cancers (Table 2). The result showed that all four miRNAs were downregulated, and miR-496 was expressed at a low level in at least 6 types of carcinomas. Thus, we chose miR-496 as our target to investigate its relationship with circRNA-DLEU2. In MOLM-13 and MV-4-11 cells, miR-496 expression was notably suppressed by the ectopic expression of circRNA-DLEU2 and significantly enhanced by the silencing of circRNA-DLEU2 with si-DLEU2 (P < 0.001), while the expression of miR-892a and miR-487a showed no significant difference after the cells were transfected with either circRNA-DLEU2 or si-DLEU2 (Fig. 4A and B). Meanwhile, miR-485 expression was upregulated after knocking down circRNA-DLEU2 (Fig. 4B) (P < 0.05). Subsequently, we used qRT-PCR to preliminarily detect the expression of miR-496 and miR-485-3p in BM samples from five AML patients who belonged to the same cohort as our 20 AML patients. The results demonstrated that miR-496 expression of AML BM samples was much lower than that of healthy controls (Fig. 4C) (P = 0.0361), while no apparent difference in miR-485-3p expression was observed between the AML samples and those from healthy controls (Fig. 4D) (P = 0.1450). Therefore, we examined the expression of miR-496 in all 20 AML BM samples and found that miR-496 expression was decreased in the AML samples compared with healthy controls (Fig. 4D) (P = 0.0008). Next, we decided to explore the downstream target of miRNA-496. The possible downstream target mRNAs of miR-496 predicted by the miRDB database and microRNA.org are listed in Table 3 and Table 4, respectively. The results were displayed in Venn diagrams through the intersection of two subsets of mRNAs predicted by the miRDB database and microRNA.org. Nine intersected predicted target mRNA candidates (CPEB3, MAN1A2, MCTP1, GRAMD3, PLSCR1, PRKACB, ASXL2, EDIL3, and CLUL1) are shown in Fig. 4F. Meanwhile, we up- or downregulated miR-496 to investigate the expression of circ-DLEU2, and the results showed that the regulation of circ-DLEU2 by miR-496 had no statistical significance (Fig. 4G and H). Next, we used the STRING database (https://string-db.org) to predict the protein-protein interaction network of our selected candidates, and because the PRKACB gene is the hub gene in this network, we picked PRKACB for the molecular mechanism study (Fig. 5).

View this table:
  • View inline
  • View popup
TABLE 1

miRNA predictiona

View this table:
  • View inline
  • View popup
TABLE 2

Expression of miRNAs in cancers

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

miR-496 was inhibited by circRNA-DLEU2 and downregulated in AML tissues. (A and B) hsa-miR-496 expression in the circRNA-DLEU2 group was significantly decreased compared to the circ-vector group. ***, P < 0.001; ns, not significant. hsa-miR-496 expression in the si-DLEU2 group was significantly increased compared to the si-ctrl group. *, P < 0.05; ***, P < 0.001. (C and D) Expression of has-miR-496 and miR-485-3p in AML and healthy tissues; n = 5. (E) hsa-miR-496 expression in AML tissues was lower than in healthy tissues; n = 20. (F) Venn diagram showing the 9 common target mRNAs of miR-496 predicted by the miRDB database and microRNA.org. (G and H) circRNA-DLEU2 expression in MOLM-13 and MV-4-11 cells. The data are shown as means and SD.

View this table:
  • View inline
  • View popup
TABLE 3

High possible targets for hsa-miR-496 in miRDBa

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 4

mRNAs targeted by hsa-miR-496 in microRNA.orga

FIG 5
  • Open in new tab
  • Download powerpoint
FIG 5

STRING database (https://string-db.org) network diagram illustrating the relationship between the 9 target mRNAs.

circRNA-DLEU2 inhibited miR-496 expression and promoted PRKACB expression.Our results indicated that the overexpression of circRNA-DLEU2 promoted the expression of PRKACB, while si-DLEU2 inhibited the expression of PRKACB in MOLM-13 and MV-4-11 cells (Fig. 6A and B) (P < 0.001). In accordance with the in vitro results, PRKACB was found to be upregulated in AML samples compared with healthy controls (Fig. 6C) (P = 0.0002). Next, we transfected miR-496 mimics and miR-496 inhibitors into MOLM-13 and MV-4-11 cells before investigating the effects of miR-496 on PRKACB expression, and the expression of the mimics and inhibitors was confirmed by qRT-PCR (Fig. 6D) (P < 0.001). We found that miR-496 mimics inhibited the expression of PRKACB (P < 0.001), which was drastically reversed by the knockdown of miR-496 by its inhibitors in the MOLM-13 and MV-4-11 cell lines, respectively (P < 0.01) (Fig. 6E and F). Altogether, we verified that PRKACB is one of the targets of miR-496 in AML cell lines.

FIG 6
  • Open in new tab
  • Download powerpoint
FIG 6

PRKACB is upregulated by circRNA-DLEU2 and downregulated by miR-496. (A and B) PRKACB mRNA expression in MOLM-13 and MV-4-11 cells after transfection with circ-DLEU2-OE or si-DLEU2. ***, P < 0.001 compared with circ-vector; **, P < 0.01 compared with si-ctrl. (C) Expression of PRKACB in AML is higher than that in a healthy control group. (D) Transfection efficiencies of miR-496 mimics and inhibitors verified by qPCR. ***, P < 0.001 compared with a mimic control group. **, P < 0.01; ***, P < 0.001 compared with an inhibitor control group. (E and F) PRKACB mRNA expression in MOLM-13 and MV-4-11 cells. ***, P < 0.001 compared with a mimic control group; **, P < 0.01 compared with an inhibitor control group. The data are shown as means and SD.

We were eager to find the exact sites of interaction between circRNA-DLEU2, miR-496, and PRKACB. We applied TargetScan (http://www.targetscan.org/vert_50/) to predict binding sites between miR-496 and circRNA-DLEU2 or miR-496 and PRKACB. The results showed that circRNA-DLEU2 had a potential binding site of miR-496, and PRKACB had two possible target sites (around 1,843 bp and 2,911 bp from its 3′ untranslated region [UTR]) of miR-496; thus, we constructed a set of mutated or wild-type circRNA-DLEU2 and PRKACB luciferase reporters (Fig. 7A). The sequence information for circRNA-DLEU2 and PRKACB is presented in Table 5 and Table 6. A luciferase reporter assay verified that circRNA-DLEU2 directly targeted miR-496 and that miR-496 could target PRKACB (Fig. 7B and C) (P < 0.01). We also performed RNA precipitation assays to verify the interaction between circRNA-DLEU2 and miR-496, as well as PRKACB. First, we confirmed the expression of probe-PRKACB and probe-circ-DLEU2 in MOL-13 cells, and the results are shown in Fig. 7D and 2C, respectively. The results indicated that the enrichment of miR-496 in the overexpressed circRNA-DLEU2 group was lower than that in the circ-vector group, while miR-496 enrichment in the PRKACB overexpression group was higher than that in the vector group (Fig. 7E and F) (P < 0.05). Hence, it can be concluded that circRNA-DLEU2 can inhibit miR-496 expression and promote PRKACB expression and that miR-496 can inhibit PRKACB expression.

FIG 7
  • Open in new tab
  • Download powerpoint
FIG 7

Target relationships between circ-DLEU2/miR-496 and PRKACB/miR-496. (A to C) TargetScan was used to predict the binding sites of circ-DLEU2/miR-496 and PRKACB/miR-496. Blue, circ-DLEU2 binding sequence; red, miR-496 binding sequence; purple, PRKACB binding sequence. **, P < 0.01 compared with a mimic control group. (D) PRKACB mRNA expression in the PRKACB-OE group was higher than that in the vector group. ***, P < 0.001 compared with the vector group. (E and F) Enrichment of circ-DLEU2 and miR-496 in MOLM-13 cells after transfection with circ-DLEU2 probe and PRKACB probe. *, P < 0.05 compared with the circ-vector group. The data are shown as means and SD.

View this table:
  • View inline
  • View popup
TABLE 5

Hsa_circ_0000488 (circRNA-DLEU2) sequencea information

View this table:
  • View inline
  • View popup
TABLE 6

PRKACB sequencea information

miR-496 antagonized the effects of PRKACB on MOLM-13 cell proliferation and apoptosis.We further investigated the molecular mechanisms of miR-496 and PRKACB in AML cells. Western blotting revealed that miR-496 impeded PRKACB protein expression while circRNA-DLEU2 increased the expression of PRKACB (Fig. 8A and B) (P < 0.001). AML cell proliferation was enhanced by PRKACB (P < 0.05), while PRKACB-mediated AML cell proliferation was reversed by miR-496. Nevertheless, the inhibition of cell proliferation induced by suppressed PRKACB was reversed by overexpressed circRNA-DLEU2 (P < 0.01) (Fig. 8C). Analogously, PRKACB significantly inhibited AML cell apoptosis (P < 0.001), which was neutralized by cotransfection with miR-496. Cotransfection of circRNA-DLEU2 and si-PRKACB showed results similar to those in the control group (P < 0.01) (Fig. 8D). Altogether, these results verified that miR-496 antagonized the effects of PRKACB on MOLM-13 cell proliferation and apoptosis.

FIG 8
  • Open in new tab
  • Download powerpoint
FIG 8

miR-496 antagonizes the effects of PRKACB on MOLM-13 cell proliferation and apoptosis. (A and B) miR-496 mimics inhibit PRKACB protein expression. **, P < 0.01 compared with the NC group, compared with the PRKACB group, and compared with the si-PRKACB group. (C) The proliferation rate in the miR-496 mimic group was lower than that in the NC group, and the proliferation rate in the PRKACB group was higher than that in the NC group. **, P < 0.01 compared with the NC group. (D) miR-496 mimics improve the apoptosis ratio. **, P < 0.01 compared with the NC group; **, P < 0.01 compared with the PRKACB group; *, P < 0.05, and **, P < 0.01 compared with the si-PRKACB group. The data are shown as means and SD.

DISCUSSION

It has been reported that circRNAs play an important role in regulating various biological processes, including leukemogenesis (4), and distinct molecular mechanisms, including the circRNA-miRNA-mRNA axis. In our present study, circRNA-DLEU2 was found to be overexpressed in both AML patients and cell lines; it promoted AML cell proliferation and inhibited apoptosis in vitro and promoted tumor formation in vivo. circRNA-DLEU2 targeted has-miR-496, and has-miR-496 targeted PRKACB. miR-496 antagonized the effects of PRKACB on MOLM-13 cell proliferation and apoptosis.

Of note, circRNAs are widely expressed in human cells, and their expression can be higher by 10-fold or more than that of their linear counterparts (26). Compared with other noncoding RNAs, the unique structure of circRNAs has been characterized as the ideal prognostic biomarker and potential therapy target due to its high stability and specific expression patterns. Some studies have reported the correlation of circRNA and AML. For example, Jeck et al. revealed that has_circ_0004277 served as a new biomarker for AML (27). In our study, circRNA-DLEU2 was found to be upregulated in AML cells and promoted cell proliferation and inhibited cell apoptosis. The roles of DLEU2 in leukemia were reported in some studies. For example, Morenos et al. demonstrated that the DLEU2 locus and embedded miRNA cluster miR-15a/16-1 were commonly deleted in adult cancers and were shown to induce leukemogenesis (28). Kasar et al. revealed that the DLEU2 promoter may augment chronic lymphocytic leukemia therapy by decreasing miR-15a/16-1 expression (29). These studies investigated the role of DLEU2 lncRNA or the DLEU2 protein as tumor suppressors, and our study first explored the molecular mechanism of circRNA-DLEU2 in AML.

Certain circRNAs can bind and negatively influence miRNAs, which are substantially involved in the competing endogenous RNA (ceRNA) network, thereby regulating linear-RNA transcription and protein production. Hansen et al. reported that circRNA ciRS-7 could strongly suppress miR-7 activity, resulting in increased levels of miR-7 (30). circRNA_100290 plays a role in oral cancer by functioning as a sponge for the miR-29 family (31). The circular RNA MYLK, as a competing endogenous RNA, promotes bladder cancer progression by modulating the vascular endothelial growth factor A/vascular endothelial growth factor receptor 2 signaling pathway (32). In our study, circRNA-DLEU2 inhibited the expression level of miR-496 by targeting miR-496, which was downregulated in AML.

To further investigate the molecular network of circRNA-DLEU2 and miR-496, we found a downstream target of miR-496: PRKACB. The experiments we performed indicated that PRKACB could be downregulated by miR-496, while circRNA-DLEU2 promoted PRKACB expression in AML cells. Some publications have reported a role of PRKACB in cancer development. For instance, PRKACB was downregulated in non-small-cell lung cancer, and exogenous PRKACB inhibited proliferation and invasion of LTEP-A2 cells (22). In contrast, PRKACB induced the cell migration of breast cancer (24). Wang et al. demonstrated that inhibition of miR-372 led to reduced translational repression of PRKACB in liver cancer (25).

To investigate the roles of circRNA-DLEU2, miR-496, and PRKACB, our next study will focus on the effects of these three molecules' cotransfection on AML cell activities, such as proliferation, metastasis, and the cell cycle. The pathway of circRNA-DLEU2 in AML is also worthy of study.

In summary, our study verified that circRNA-DLEU2 was upregulated in AML and that it promoted the proliferation of AML cells and inhibited cell apoptosis. Additionally, the target relationships of circRNA-DLEU2/miR-496 and miR-496/PRKACB were clarified by a series of experiments. Although we do not know what the in vivo role of circ-DLEU2 in the pathphysiological genesis of human AML might be, this could be an interesting question to answer in future research. Our study suggested that circRNA-DLEU2 may serve as a novel biomarker and therapeutic target of human AML by targeting the miR-496/PRKACB channel.

MATERIALS AND METHODS

Tissue samples.BM samples were collected from a cohort of 20 CN-AML patients and 20 healthy controls between 2012 and 2016 at Gulou Hospital Affiliated to Medical College of Nanjing University without prior chemotherapy or radiation treatment. Informed consent was obtained from all the patients and healthy controls before surgery. This study was approved by the Ethical Committee of Gulou Hospital Affiliated to Medical College of Nanjing University. Clinical information for the AML patients is shown in Table 7 and Table 8. All BM samples were independently reviewed by three clinicians.

View this table:
  • View inline
  • View popup
TABLE 7

Clinical information for acute myeloid leukemia patients

View this table:
  • View inline
  • View popup
TABLE 8

Characteristics of AML patients

Cell culture.Three human AML cell lines (MOLM-13, MV-4-11, and HL-60), normal cells (bone marrow stem cells [BMSC]), and HEK293 cells were purchased from the BeNa Culture Collection (Beijing, China). AML and BMSC were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and lipopolysaccharide from Escherichia coli (10 μg/ml). HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, St. Louis, MO) supplemented with 10% (vol/vol) FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO). All the cells were maintained in an incubator with a 5% CO2 atmosphere at 37°C.

Microarray analysis.Affymetrix microarray platform GPL19978 and microarray data set GSE94591, used for bioinformatics analyses, were obtained from the NCBI Gene Expression Omnibus (GEO) database. The GSE94591 data set contained 10 samples: 4 healthy controls and 6 CN-AML patients' samples (3 poor-risk AML samples and 3 better-risk AML samples). A log2-fold change of >1.5 or less than −1.5 and a P value of <0.05 were set as inclusive criteria to search for differentially expressed circRNAs.

Transfection.circ-DLEU2 and PRKACB were cloned into pLCDH (Geneseed Biotech, Shanghai, China) and pcDNA3.1 (BioVector NTCC Inc., Beijing, China), respectively. circ-DLEU2 small interfering RNA (siRNA), hsa-miR-496 mimics, hsa-miR-496 inhibitors, si-ctrl, and circ-vector were purchased from GenePharma Co., Ltd. (Shanghai, China). The sequences of all the recombinant plasmids were confirmed by DNA sequencing. circRNAs were confirmed by both convergent and divergent primers and Northern blotting. Cells were seeded onto petri dishes or 6-well plates for 24 h, and when the cells reached 80% confluence, transfections were carried out using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. Then, the transfected cells were cultured for 24 to 72 h with 5% CO2 at 37°C before being used in other experiments.

qRT-PCR.Total RNA from 20 samples was isolated using TRIzol reagent (Invitrogen). For extracting circRNA, the extracted total RNA was treated with RNase R (Epicenter Inc.) and digested at 37°C for 20 min. Then, the RNA was quantitated using a NanoDrop 2000 (Thermo Fisher Scientific Inc.) and reverse transcribed into cDNA using a cDNA synthesis kit (Thermo Fisher) with a total mass of 200 ng total RNA. Quantitative real-time PCR was conducted using Thunderbird SYBR qPCR mix (Toyobo, Japan). The PCR conditions were as follows: denaturation at 94°C for 2 min, followed by a further 30 cycles of denaturation at 94°C for 30 s and finally annealing at 56°C for 30 s. All reactions were performed in four independent trials. The primer sequences are listed in Table 9. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal control for mRNA and circRNA qRT-PCR, while the miRNA expression was normalized to that of U6 small nuclear RNA (U6). The relative circRNA, mRNA, and miRNA expression fold changes were calculated using the 2−ΔΔCT method.

View this table:
  • View inline
  • View popup
TABLE 9

Primer sequences

CCK8 assay.In the wells of a 96-well plate, 8 × 103 MOLM-13 or MV-4-11 cells were seeded and incubated overnight. At 0, 24, 48, and 72 h after transfection, cell growth and viability rates were measured using a CCK8 kit (Biotechwell, Shanghai, China) according to the manufacturer's instructions. Absorbance was measured at 450 nm in a SpectraMax M5 multimode plate reader (Molecular Devices). All experiments were conducted with six replicates and repeated in triplicate.

Apoptosis analysis.MOLM-13 and MV-4-11 cells were treated with a phycoerythrin (PE)-annexin V-fluorescein isothiocyanate (FITC) apoptosis assay kit (BD) for 48 h after transfection. The cells were analyzed with a FACSCalibur (BD), and the data were processed using FACS Diva (BD). All experiments were conducted with six replicates and repeated in triplicate.

Luciferase reporter assay.The luciferase vector psiCHECK (Hanhbio, Shanghai, China) was used to construct recombinant plasmids, including wild-type and mutant circRNA-DLEU2, wild-type PRKACB, and mutant PRKACB 3′ UTR. Different recombinant plasmids were cotransfected into HEK293 cells with either miR-496 mimics or mimic control. The luciferase activity of each transfection group was detected using a luciferase activity detecting kit (Luc-100; Biothrive, Shanghai, China) 48 h after transfection with a SpectraMax M5 multimode plate reader (Molecular Devices).

RNA precipitation.Biotin-labeled circRNA-DLEU2 probe (5′-TGACAGCCTAACACAGTTTTAGATGGAGTTTGGCTTGGTTTTCTT-3′-biotin) and biotin-labeled PRKACB probe (5′-AGAAGTTGTTTCCAGCTAATTATTGTGGTGTACTATATTTGTGAGCCTAG-3′-biotin) were synthesized by Sangon Biotech. circRNA-DLEU2-overexpressing (OE) and PRKACB-overexpressing MOLM-13 cells were fixed with 1% formaldehyde for 10 min, lysed, and sonicated. After centrifugation, 50 μl of the supernatant was retained as input, and the remaining part was incubated with circRNA-DLEU2- and PRKACB-specific probes attached to streptavidin-coupled Dynabeads (M-280; Invitrogen). The mixture was incubated overnight at 30°C. The next day, the M-280 Dynabead-probe-RNA mixture was washed and incubated with 200 μl lysis buffer and proteinase K to reverse the formaldehyde cross-linking. Finally, TRIzol was added to the mixture for RNA extraction and detection.

Western blotting.Transfected cells were washed with phosphate-buffered saline (PBS) before total protein was extracted with radioimmunoprecipitation assay (RIPA) lysate (Beyotime, Shanghai, China) supplemented with protease inhibitor cocktail (Roche, Basel, Switzerland), separated on SDS-PAGE gels, and transferred to polyvinylidene difluoride (PVDF) membranes. Following overnight hybridization with monoclonal anti-PRKACB and anti-GAPDH antibodies (Abcam, Cambridge, MA) at 4°C, the membranes were incubated with horseradish peroxidase (HRP)-labeled secondary antibody (Abcam) at room temperature for 1 h. Finally, enhanced chemiluminescence (ECL Plus; Life Technology, Shanghai, China) was used for protein signal detection, and Lab Works 4.5 was applied for image capture and ImageJ (https://imagej.nih.gov/ij/) for relative quantification to calculate the mean gray value of immunoreactive bands against GAPDH bands (as an internal control).

Subcutaneous xenografts.Male C57BL/6 mice (7 weeks old; n = 5) were obtained from the Experimental Animal Center of Zhejiang University (Zhejiang, China). For the subcutaneous xenograft model, 3 groups of 5 mice each were injected subcutaneously at the same site with 107 prepared cells. Tumor volume was calculated using the following formula: V = (L × W2) × 0.5, where V refers to volume, W refers to the short axial length, and L refers to the long axial length. Five weeks after injection, the mice were sacrificed and examined.

Research involving human subjects or animal experimentation were in line with the Requirements and Regulations for Human Subjects or Animal Experiments of the National Health Ministry (article no. 55, 2001, or no. 17, 1999) and the principles of the Ethics Committee of the Affiliated Municipal Hospital of Xuzhou. All efforts were made to minimize the pain of the animals.

Statistical analysis.All data are represented as means and standard deviations (SD). A P value of <0.05 was considered statistically significant. Unpaired Student t tests were used to compare the differences between two groups. One-way analysis of variance (ANOVA) with the Bonferroni post hoc test was used to compare the differences in multiple groups. Each experiment was independently repeated at least three times.

ACKNOWLEDGMENTS

This work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the 2016 333 Project Award of Jiangsu Province, the 2013 Qinglan Project of the Young and Middle-Aged Academic Leader of Jiangsu College and University, the National Natural Science Foundation of China (81571055, 81400902, 81271225, 31201039, 81171012, and 30950031), the Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (13KJA180001), and grants from the Cultivate National Science Fund for Distinguished Young Scholars of Jiangsu Normal University.

We declare that we have no conflict of interest.

FOOTNOTES

    • Received 21 May 2018.
    • Returned for modification 16 June 2018.
    • Accepted 16 July 2018.
    • Accepted manuscript posted online 23 July 2018.

REFERENCES

  1. 1.↵
    1. Wen S,
    2. Wang J,
    3. Liu P,
    4. Li Y,
    5. Lu W,
    6. Hu Y,
    7. Liu J,
    8. He Z,
    9. Huang P
    . 2018. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo. Cancer Lett 413:35–45. doi:10.1016/j.canlet.2017.10.015.
    OpenUrlCrossRef
  2. 2.↵
    1. Sill H,
    2. Olipitz W,
    3. Zebisch A,
    4. Schulz E,
    5. Wolfler A
    . 2011. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 162:792–805. doi:10.1111/j.1476-5381.2010.01100.x.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Uchida H,
    2. Inokuchi K,
    3. Watanabe R,
    4. Tokuhira M,
    5. Kizaki M
    . 2008. New therapeutic approaches to acute myeloid leukemia. Expert Opin Drug Discov 3:689–706. doi:10.1517/17460441.3.6.689.
    OpenUrlCrossRef
  4. 4.↵
    1. Li W,
    2. Zhong C,
    3. Jiao J,
    4. Li P,
    5. Cui B,
    6. Ji C,
    7. Ma D
    . 2017. Characterization of hsa_circ_0004277 as a new biomarker for acute myeloid leukemia via circular RNA profile and bioinformatics analysis. Int J Mol Sci 18:E597. doi:10.3390/ijms18030597.
    OpenUrlCrossRef
  5. 5.↵
    1. Sabattini E,
    2. Bacci F,
    3. Sagramoso C,
    4. Pileri SA
    . 2010. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102:83–87.
    OpenUrlPubMed
  6. 6.↵
    1. Briedigkeit H,
    2. Halle E
    . 1989. Calculated antimicrobial chemotherapy from the viewpoint of the clinical microbiologist. Z Arztl Fortbild 83:295–299.
    OpenUrl
  7. 7.↵
    1. Szabo L,
    2. Morey R,
    3. Palpant NJ,
    4. Wang PL,
    5. Afari N,
    6. Jiang C,
    7. Parast MM,
    8. Murry CE,
    9. Laurent LC,
    10. Salzman J
    . 2015. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. Genome Biol 16:126. doi:10.1186/s13059-015-0690-5.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Vausort M,
    2. Salgado-Somoza A,
    3. Zhang L,
    4. Leszek P,
    5. Scholz M,
    6. Teren A,
    7. Burkhardt R,
    8. Thiery J,
    9. Wagner DR,
    10. Devaux Y
    . 2016. Myocardial infarction-associated circular RNA predicting left ventricular dysfunction. J Am Coll Cardiol 68:1247–1248. doi:10.1016/j.jacc.2016.06.040.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Zheng Q,
    2. Bao C,
    3. Guo W,
    4. Li S,
    5. Chen J,
    6. Chen B,
    7. Luo Y,
    8. Lyu D,
    9. Li Y,
    10. Shi G,
    11. Liang L,
    12. Gu J,
    13. He X,
    14. Huang S
    . 2016. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun 7:11215. doi:10.1038/ncomms11215.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Gao YL,
    2. Zhang MY,
    3. Xu B,
    4. Han LJ,
    5. Lan SF,
    6. Chen J,
    7. Dong YJ,
    8. Cao LL
    . 2017. Circular RNA expression profiles reveal that hsa_circ_0018289 is up-regulated in cervical cancer and promotes the tumorigenesis. Oncotarget 8:86625–86633. doi:10.18632/oncotarget.21257.
    OpenUrlCrossRef
  11. 11.↵
    1. Zhang H,
    2. Wang G,
    3. Ding C,
    4. Liu P,
    5. Wang R,
    6. Ding W,
    7. Tong D,
    8. Wu D,
    9. Li C,
    10. Wei Q,
    11. Zhang X,
    12. Li D,
    13. Liu P,
    14. Cui H,
    15. Tang H,
    16. Ji F
    . 2017. Increased circular RNA UBAP2 acts as a sponge of miR-143 to promote osteosarcoma progression. Oncotarget 8:61687–61697. doi:10.18632/oncotarget.18671.
    OpenUrlCrossRef
  12. 12.↵
    1. Memczak S,
    2. Jens M,
    3. Elefsinioti A,
    4. Torti F,
    5. Krueger J,
    6. Rybak A,
    7. Maier L,
    8. Mackowiak SD,
    9. Gregersen LH,
    10. Munschauer M,
    11. Loewer A,
    12. Ziebold U,
    13. Landthaler M,
    14. Kocks C,
    15. le Noble F,
    16. Rajewsky N
    . 2013. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495:333–338. doi:10.1038/nature11928.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Hirsch S,
    2. Blatte TJ,
    3. Grasedieck S,
    4. Cocciardi S,
    5. Rouhi A,
    6. Jongen-Lavrencic M,
    7. Paschka P,
    8. Kronke J,
    9. Gaidzik VI,
    10. Dohner H,
    11. Schlenk RF,
    12. Kuchenbauer F,
    13. Dohner K,
    14. Dolnik A,
    15. Bullinger L
    . 2017. Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. Haematologica 102:2039–2047. doi:10.3324/haematol.2017.172866.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. L'Abbate A,
    2. Tolomeo D,
    3. Cifola I,
    4. Severgnini M,
    5. Turchiano A,
    6. Augello B,
    7. Squeo G,
    8. D'Addabbo P,
    9. Traversa D,
    10. Daniele G,
    11. Lonoce A,
    12. Pafundi M,
    13. Carella M,
    14. Palumbo O,
    15. Dolnik A,
    16. Muehlematter D,
    17. Schoumans J,
    18. Van Roy N,
    19. De Bellis G,
    20. Martinelli G,
    21. Merla G,
    22. Bullinger L,
    23. Haferlach C,
    24. Storlazzi CT
    . 22 February 2018. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. doi:10.1038/s41375-018-0033-0.
    OpenUrlCrossRef
  15. 15.↵
    1. Xiao Y,
    2. Deng T,
    3. Su C,
    4. Shang Z
    . 2017. MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncol Lett 13:4986–4994. doi:10.3892/ol.2017.6076.
    OpenUrlCrossRef
  16. 16.↵
    1. Balatti V,
    2. Pekarky Y,
    3. Croce CM
    . 2015. Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol 8:12. doi:10.1186/s13045-015-0112-x.
    OpenUrlCrossRef
  17. 17.↵
    1. He L,
    2. Hannon GJ
    . 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531. doi:10.1038/nrg1379.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Zhang TJ,
    2. Wu DH,
    3. Zhou JD,
    4. Li XX,
    5. Zhang W,
    6. Guo H,
    7. Ma JC,
    8. Deng ZQ,
    9. Lin J,
    10. Qian J
    . 2018. Overexpression of miR-216b: prognostic and predictive value in acute myeloid leukemia. J Cell Physiol 233:3274–3281. doi:10.1002/jcp.26171.
    OpenUrlCrossRef
  19. 19.↵
    1. Li Z,
    2. Huang H,
    3. Li Y,
    4. Jiang X,
    5. Chen P,
    6. Arnovitz S,
    7. Radmacher MD,
    8. Maharry K,
    9. Elkahloun A,
    10. Yang X,
    11. He C,
    12. He M,
    13. Zhang Z,
    14. Dohner K,
    15. Neilly MB,
    16. Price C,
    17. Lussier YA,
    18. Zhang Y,
    19. Larson RA,
    20. Le Beau MM,
    21. Caligiuri MA,
    22. Bullinger L,
    23. Valk PJ,
    24. Delwel R,
    25. Lowenberg B,
    26. Liu PP,
    27. Marcucci G,
    28. Bloomfield CD,
    29. Rowley JD,
    30. Chen J
    . 2012. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 119:2314–2324. doi:10.1182/blood-2011-10-386235.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Wang Y,
    2. Li Z,
    3. He C,
    4. Wang D,
    5. Yuan X,
    6. Chen J,
    7. Jin J
    . 2010. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 44:191–197. doi:10.1016/j.bcmd.2009.12.010.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Skalhegg BS,
    2. Tasken K
    . 2000. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 5:D678–D693.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Chen Y,
    2. Gao Y,
    3. Tian Y,
    4. Tian DL
    . 2013. PRKACB is downregulated in non-small cell lung cancer and exogenous PRKACB inhibits proliferation and invasion of LTEP-A2 cells. Oncol Lett 5:1803–1808. doi:10.3892/ol.2013.1294.
    OpenUrlCrossRef
  23. 23.↵
    1. Pashaei E,
    2. Pashaei E,
    3. Ahmady M,
    4. Ozen M,
    5. Aydin N
    . 2017. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One 12:e0179543. doi:10.1371/journal.pone.0179543.
    OpenUrlCrossRef
  24. 24.↵
    1. Sigloch FC,
    2. Burk UC,
    3. Biniossek ML,
    4. Brabletz T,
    5. Schilling O
    . 2015. miR-200c dampens cancer cell migration via regulation of protein kinase A subunits. Oncotarget 6:23874–23889. doi:10.18632/oncotarget.4381.
    OpenUrlCrossRef
  25. 25.↵
    1. Wang J,
    2. Liu X,
    3. Wu H,
    4. Ni P,
    5. Gu Z,
    6. Qiao Y,
    7. Chen N,
    8. Sun F,
    9. Fan Q
    . 2010. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38:5366–5383. doi:10.1093/nar/gkq285.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Ivanov A,
    2. Memczak S,
    3. Wyler E,
    4. Torti F,
    5. Porath HT,
    6. Orejuela MR,
    7. Piechotta M,
    8. Levanon EY,
    9. Landthaler M,
    10. Dieterich C,
    11. Rajewsky N
    . 2015. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep 10:170–177. doi:10.1016/j.celrep.2014.12.019.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Jeck WR,
    2. Sorrentino JA,
    3. Wang K,
    4. Slevin MK,
    5. Burd CE,
    6. Liu J,
    7. Marzluff WF,
    8. Sharpless NE
    . 2013. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19:141–157. doi:10.1261/rna.035667.112.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Morenos L,
    2. Chatterton Z,
    3. Ng JL,
    4. Halemba MS,
    5. Parkinson-Bates M,
    6. Mechinaud F,
    7. Elwood N,
    8. Saffery R,
    9. Wong NC
    . 2014. Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer 13:123. doi:10.1186/1476-4598-13-123.
    OpenUrlCrossRef
  29. 29.↵
    1. Kasar S,
    2. Underbayev C,
    3. Yuan Y,
    4. Hanlon M,
    5. Aly S,
    6. Khan H,
    7. Chang V,
    8. Batish M,
    9. Gavrilova T,
    10. Badiane F,
    11. Degheidy H,
    12. Marti G,
    13. Raveche E
    . 2014. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene 33:3307–3315. doi:10.1038/onc.2013.291.
    OpenUrlCrossRef
  30. 30.↵
    1. Hansen TB,
    2. Jensen TI,
    3. Clausen BH,
    4. Bramsen JB,
    5. Finsen B,
    6. Damgaard CK,
    7. Kjems J
    . 2013. Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. doi:10.1038/nature11993.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Zhong Z,
    2. Huang M,
    3. Lv M,
    4. He Y,
    5. Duan C,
    6. Zhang L,
    7. Chen J
    . 2017. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett 403:305–317. doi:10.1016/j.canlet.2017.06.027.
    OpenUrlCrossRef
  32. 32.↵
    1. Chen L,
    2. Zhang S,
    3. Wu J,
    4. Cui J,
    5. Zhong L,
    6. Zeng L,
    7. Ge S
    . 2017. circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. Oncogene 36:4551–4561. doi:10.1038/onc.2017.89.
    OpenUrlCrossRefPubMed
  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

PreviousNext
Back to top
Download PDF
Citation Tools
Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia
Dong-Mei Wu, Xin Wen, Xin-Rui Han, Shan Wang, Yong-Jian Wang, Min Shen, Shao-Hua Fan, Zi-Feng Zhang, Qun Shan, Meng-Qiu Li, Bin Hu, Gui-Quan Chen, Jun Lu, Yuan-Lin Zheng
Molecular and Cellular Biology Sep 2018, 38 (20) e00259-18; DOI: 10.1128/MCB.00259-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Molecular and Cellular Biology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia
(Your Name) has forwarded a page to you from Molecular and Cellular Biology
(Your Name) thought you would be interested in this article in Molecular and Cellular Biology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia
Dong-Mei Wu, Xin Wen, Xin-Rui Han, Shan Wang, Yong-Jian Wang, Min Shen, Shao-Hua Fan, Zi-Feng Zhang, Qun Shan, Meng-Qiu Li, Bin Hu, Gui-Quan Chen, Jun Lu, Yuan-Lin Zheng
Molecular and Cellular Biology Sep 2018, 38 (20) e00259-18; DOI: 10.1128/MCB.00259-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

AML
PRKACB
circRNA-DLEU2
hsa-miR-496

Related Articles

Cited By...

About

  • About MCB
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #MCBJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0270-7306; Online ISSN: 1098-5549